Equine Viral Arteritis (EVA)

Equine Viral Arteritis vaccine is a modified live virus immunization designed to protect horses against infection with the equine arteritis virus, a highly contagious pathogen that can cause significant reproductive and respiratory disease in equine populations. This risk-based vaccine is considered essential for horses involved in breeding programs and those with high exposure risk at facilities where the virus may be present. The vaccine has proven highly effective at preventing clinical disease and reducing viral shedding when administered according to recommended protocols.

The equine arteritis virus belongs to the family Arteriviridae and primarily targets the respiratory system and reproductive organs of infected horses. When a horse receives the EVA vaccine, the modified live virus stimulates the immune system to produce antibodies against the pathogen without causing actual disease. This immune response provides protection that can last for extended periods, though booster vaccinations are recommended to maintain optimal immunity. The vaccine works by mimicking natural infection closely enough to generate robust immunity while being attenuated sufficiently to prevent clinical signs.

The EVA vaccine is available as an injectable suspension administered intramuscularly by a licensed veterinarian. Unlike some other equine vaccines that may be administered by trained horse owners, EVA vaccination requires veterinary oversight due to specific regulatory requirements and the need for proper documentation. The vaccine typically comes in single-dose vials and must be reconstituted before administration according to manufacturer guidelines. Most horses receive the vaccine in the neck musculature, and the procedure is generally well-tolerated with minimal discomfort.

The safety profile of the EVA vaccine is generally favorable when administered to appropriate candidates under veterinary supervision. However, this vaccine carries specific restrictions that make proper patient selection critically important. Pregnant mares, for instance, should not receive this modified live virus vaccine due to the risk of fetal infection and abortion. Veterinary guidance is essential not only for proper administration but also for navigating the regulatory requirements surrounding EVA vaccination, including testing protocols and documentation for interstate movement and international competition.

The primary indication for EVA vaccination is the prevention of equine viral arteritis in horses at elevated risk of exposure to the virus. Equine viral arteritis is a contagious disease that can cause a range of clinical signs including fever, depression, limb swelling, conjunctivitis, nasal discharge, and most significantly, abortion in pregnant mares. Stallions can become persistently infected and shed the virus in their semen for months or even years, making them ongoing sources of infection for susceptible mares. Vaccination breaks this cycle by preventing initial infection or reducing the severity of disease and viral shedding.

Breeding stallions represent the highest priority population for EVA vaccination. A stallion that becomes infected with the equine arteritis virus may become a carrier, continuously shedding virus in his semen and potentially infecting every mare he breeds. Vaccinating stallions before they reach sexual maturity or before potential exposure prevents this carrier state from developing. Once a stallion becomes a shedder, vaccination cannot eliminate the persistent infection, making prevention through early vaccination the only effective strategy. Breed registries and many breeding facilities now require documentation of EVA vaccination status or negative testing for participating stallions.

Mares entering breeding programs, particularly those being bred to stallions of unknown EVA status or those traveling to breeding facilities with multiple horses, benefit significantly from vaccination. While mares do not become persistent shedders like stallions, acute infection can cause abortion, which represents a devastating economic and emotional loss. Vaccinated mares develop immunity that protects both themselves and their developing foals from the consequences of EVA infection. Mares should be vaccinated well before breeding to allow adequate time for immunity to develop.

Horses traveling to shows, sales, or events where they may encounter horses from diverse geographic regions face increased EVA exposure risk. The virus has variable prevalence across different horse populations and geographic areas, with certain breeds and regions showing higher infection rates. Competition horses, sale horses, and those housed at large training facilities with frequent horse movement represent populations where risk-based EVA vaccination should be considered. The decision to vaccinate should be made in consultation with a veterinarian who can assess individual risk factors.

Veterinary professionals may also recommend EVA vaccination for horses at facilities experiencing an outbreak or those with known exposure to infected animals. In outbreak situations, vaccination of uninfected horses can help limit viral spread and protect the remaining susceptible population. However, vaccination cannot treat horses already infected, and proper quarantine measures must accompany any vaccination response to an active outbreak. The strategic use of EVA vaccine as part of a comprehensive biosecurity program helps protect valuable breeding stock and performance horses from this economically significant disease.

The administration of EVA vaccine follows specific protocols that must be tailored to the individual horse's circumstances, age, and intended use. All vaccination decisions and administration should be performed by or under the direct supervision of a licensed veterinarian, as regulatory requirements and proper documentation are essential components of EVA vaccination programs. The veterinarian will determine the appropriate vaccination schedule based on the horse's risk factors, breeding status, and any applicable regulatory requirements for the horse's intended activities.

The standard primary vaccination protocol for horses without previous EVA exposure typically involves a single dose of the modified live virus vaccine administered intramuscularly. For stallions, vaccination is ideally performed before the onset of puberty or at minimum several weeks before the beginning of the breeding season. This timing allows the immune system to develop protective antibodies before any potential exposure through breeding activities. Mares should similarly be vaccinated well in advance of breeding, with most protocols recommending vaccination at least three weeks before exposure to ensure adequate immunity has developed.

Booster vaccinations are recommended to maintain protective immunity, though the optimal interval may vary based on exposure risk and individual circumstances. Many veterinarians recommend annual revaccination for horses in ongoing breeding programs or those with continued exposure risk. Stallions at active breeding facilities may require more frequent monitoring of their immune status, and some protocols call for revaccination before each breeding season. The veterinarian will establish an appropriate booster schedule based on the horse's specific situation and the current disease pressure in the area.

The vaccine is administered via intramuscular injection, typically in the large muscle masses of the neck or hindquarters. The injection site should be clean and dry, and proper aseptic technique must be maintained throughout the procedure. Most horses tolerate the injection well with minimal reaction, though mild transient soreness at the injection site is not uncommon. The vaccine must be handled according to manufacturer specifications, including proper reconstitution if required and use within the specified timeframe after preparation.

Pre-vaccination testing is a critical component of EVA vaccination protocols, particularly for stallions. Before initial vaccination, horses should be tested for EVA antibodies to establish whether they are seronegative and eligible for vaccination or seropositive due to previous exposure or infection. This testing is not only important for proper vaccination decisions but also required by many breed registries and regulatory bodies. A horse that tests seropositive cannot be distinguished from a vaccinated horse through standard antibody testing, making pre-vaccination documentation essential for demonstrating vaccine-induced rather than infection-induced seropositivity.

Post-vaccination isolation is required for recently vaccinated horses, as the modified live virus can potentially be transmitted to susceptible horses for a period following vaccination. Stallions should be isolated from seronegative mares for at least three weeks after vaccination to prevent inadvertent transmission. This isolation requirement underscores the importance of strategic timing when planning EVA vaccination and the need for facilities to have appropriate isolation capabilities. Veterinarians will provide specific guidance on isolation duration and monitoring requirements based on current recommendations and facility circumstances.

The EVA vaccine is generally well-tolerated by most horses when administered according to label directions and veterinary guidance. As with any biological product designed to stimulate an immune response, some degree of reaction is expected and typically indicates the immune system is responding appropriately to the vaccine antigens. Most side effects are mild and transient, resolving without intervention within a few days of vaccination. However, horse owners should monitor vaccinated animals and report any concerning reactions to their veterinarian promptly.

The most commonly observed side effects following EVA vaccination include mild swelling, warmth, or tenderness at the injection site. This local reaction typically develops within the first day or two after vaccination and resolves spontaneously within three to five days. Some horses may show slight stiffness or reluctance to flex the neck if vaccinated in the neck musculature. These local reactions are generally considered normal immune responses and rarely require treatment beyond rest and monitoring. Cold compresses or gentle massage may provide comfort but are usually unnecessary.

Systemic reactions, while less common than local injection site reactions, may occur in some horses following EVA vaccination. These can include mild fever, decreased appetite, lethargy, or general malaise lasting one to three days post-vaccination. Horses experiencing these symptoms should be rested and monitored, with strenuous exercise avoided until symptoms resolve. If fever exceeds 103 degrees Fahrenheit or persists beyond 48 hours, veterinary evaluation is warranted. Non-steroidal anti-inflammatory medications may be prescribed for horses with pronounced systemic reactions, though routine use is not recommended as it may potentially interfere with immune response development.

More significant adverse reactions are uncommon but can occur. Allergic reactions, though rare, may manifest as hives, facial swelling, or in severe cases, anaphylaxis. Horses with a history of vaccine reactions should be closely monitored following any vaccination, and veterinarians may recommend pre-treatment with antihistamines for horses with known sensitivities. Any signs of difficulty breathing, severe swelling, or collapse following vaccination constitute a veterinary emergency requiring immediate attention.

Because the EVA vaccine is a modified live virus product, there are specific concerns related to viral shedding that distinguish it from killed vaccine products. Vaccinated stallions may shed vaccine virus in their semen for a period following vaccination, which is why isolation from susceptible mares is required. Additionally, vaccination of pregnant mares is contraindicated due to the risk of fetal infection and abortion. These unique considerations related to the live nature of the vaccine underscore the importance of proper patient selection and timing of vaccination. Any mare suspected to be pregnant should not receive this vaccine, and pregnancy testing may be recommended before vaccination in mares of unknown status.

The most critical contraindication for EVA vaccination involves pregnant mares. Because this is a modified live virus vaccine, administration to pregnant mares carries a significant risk of transplacental infection and subsequent abortion. The vaccine virus can cross the placenta and infect the developing fetus, potentially causing fetal death at any stage of gestation. Mares should be confirmed not pregnant before vaccination, either through veterinary examination, ultrasound, or reliable breeding records. Any mare of breeding age with unknown pregnancy status should be evaluated before vaccination is considered.

Horses with known hypersensitivity to any component of the vaccine should not receive EVA vaccination. This includes horses that have experienced severe allergic reactions to previous doses of the same vaccine or to other vaccines containing similar components. Allergic reactions can range from mild hives to life-threatening anaphylaxis, and horses with documented severe reactions require careful evaluation before any subsequent vaccination. In some cases, the risk of vaccination may be outweighed by the potential for adverse reaction, and alternative protective strategies such as strict biosecurity may be more appropriate.

Immunocompromised horses present a particular concern with modified live virus vaccines. Horses receiving immunosuppressive therapy, those with immune-mediated conditions, or foals with known immunodeficiency disorders may be unable to mount an appropriate immune response and could potentially develop clinical disease from the vaccine virus. Horses that are significantly debilitated, under severe stress, or fighting concurrent infections should have vaccination postponed until their overall health status improves. A healthy immune system is essential for both safe handling of the modified live vaccine virus and development of protective immunity.

Timing considerations around other vaccinations and medical treatments can create relative contraindications for EVA vaccination. Administration of EVA vaccine should be appropriately spaced from other vaccines to allow proper immune response to each antigen and to avoid overwhelming the immune system. Horses undergoing treatment with corticosteroids or other immunomodulating medications may have diminished vaccine response and should have vaccination timing coordinated with their treatment schedule. The veterinarian will assess each horse's complete medical picture when determining vaccination eligibility and optimal timing.

The potential for interactions between EVA vaccine and other medications or vaccines requires careful consideration when planning vaccination protocols. While specific drug interaction studies with EVA vaccine are limited, general principles of vaccine immunology and concurrent medication use guide veterinary recommendations. Communication with the veterinarian about all medications and supplements the horse is receiving is essential for optimal vaccination planning and response.

Corticosteroids and other immunosuppressive medications can significantly impact the immune response to vaccination. These drugs suppress immune function, which may result in inadequate antibody production following EVA vaccination and potentially leave the horse susceptible to infection despite vaccination. Ideally, EVA vaccination should be delayed until immunosuppressive therapy has been discontinued for an appropriate period, typically at least two weeks depending on the specific medication and duration of use. Horses that must remain on immunosuppressive therapy may require alternative strategies for EVA protection, such as strict biosecurity measures and avoidance of high-risk situations.

The timing of EVA vaccination relative to other vaccines requires consideration to ensure optimal immune response to each product. Administering multiple vaccines simultaneously can potentially overwhelm the immune system or result in interference between vaccine antigens. Most vaccination protocols recommend spacing different vaccines by at least two to four weeks when possible. However, the specific recommendations may vary based on the vaccines involved and the horse's individual circumstances. The veterinarian will develop a comprehensive vaccination schedule that appropriately spaces EVA vaccine from other routine immunizations.

Non-steroidal anti-inflammatory drugs administered around the time of vaccination have theoretical potential to affect immune response, though clinical significance in horses is not well established. Some practitioners recommend avoiding NSAID administration for 24 to 48 hours before and after vaccination unless clinically necessary. However, horses experiencing significant post-vaccination discomfort may benefit from judicious NSAID use, and the priority should always be the horse's comfort and welfare. Antimicrobial medications are generally not expected to interfere with viral vaccine response, but the underlying condition requiring antibiotic treatment might itself be a reason to postpone vaccination until the horse has recovered.

Regulatory requirements surrounding EVA vaccination are complex and vary by jurisdiction, breed registry, and intended use of the horse. Before vaccinating any horse against EVA, veterinarians and owners must be aware of the testing and documentation requirements that apply to their specific situation. Many breed registries require pre-vaccination serology testing to establish that the horse is seronegative before vaccination, as post-vaccination antibody titers cannot be distinguished from those resulting from natural infection. Failure to document pre-vaccination seronegative status can result in a horse being classified as a potential carrier, with significant implications for breeding use and movement.

The modified live nature of the EVA vaccine necessitates specific precautions not required with killed vaccine products. Vaccinated stallions can shed vaccine virus in their semen for approximately three weeks following vaccination and must be isolated from susceptible mares during this period. Failure to maintain appropriate isolation can result in transmission of vaccine virus to unvaccinated horses, potentially complicating their serological status and breeding eligibility. Facilities must have adequate isolation capabilities before undertaking EVA vaccination of stallions.

Timing of vaccination relative to breeding activities requires careful planning. Stallions should ideally be vaccinated well before the breeding season begins, allowing time for isolation and development of immunity. Mares should be vaccinated and confirmed immune before being exposed to stallions of unknown EVA status. Vaccination during the breeding season is complicated by isolation requirements and the need to avoid vaccinating pregnant mares. Annual revaccination timing should be coordinated with breeding schedules to minimize disruption to reproductive programs.

Horses intended for international movement face additional regulatory considerations regarding EVA vaccination and testing. Different countries have varying requirements for EVA status, and some may not accept vaccinated horses or may require specific testing protocols. Owners planning international travel or competition should consult with their veterinarian and appropriate regulatory authorities well in advance to ensure compliance with destination country requirements. Documentation of vaccination, including pre-vaccination serology results, must be carefully maintained and may need to be in specific formats for international acceptance.

Competition horses must be aware that EVA vaccination status may affect eligibility for certain events, particularly those with international participation. While vaccination itself is not prohibited, the regulatory requirements and documentation can be complex. Horses competing under FEI rules or other international governing bodies should have their EVA status clarified well before competition. Additionally, some competitions may have specific biosecurity requirements during EVA outbreaks that could affect vaccinated and unvaccinated horses differently.

Proper storage of EVA vaccine is essential for maintaining product efficacy and ensuring vaccinated horses receive full protection. As a modified live virus vaccine, this product is particularly sensitive to temperature variations and improper handling that can inactivate the vaccine virus and render the product ineffective. Veterinary clinics and facilities storing EVA vaccine must maintain strict cold chain protocols from receipt through administration.

The vaccine must be stored under refrigeration at temperatures between 35 and 45 degrees Fahrenheit, protected from light and freezing. Freezing can damage the vaccine virus and carrier proteins, resulting in loss of potency. Temperature fluctuations during storage can similarly compromise vaccine effectiveness. Facilities should use calibrated refrigerators with temperature monitoring and alarm systems to ensure consistent storage conditions. The vaccine should never be stored in the door compartment of a refrigerator where temperatures fluctuate most significantly.

Once reconstituted or removed from refrigeration, EVA vaccine must be used within the timeframe specified by the manufacturer, typically within one to two hours. Exposure to room temperature accelerates degradation of the modified live virus, and delays in administration after preparation can result in reduced vaccine potency. Only the amount of vaccine needed for immediate use should be prepared, and any unused reconstituted vaccine must be properly disposed of rather than stored for later use. Proper disposal of unused vaccine, including sharps and vaccine vials, should follow veterinary medical waste protocols to prevent environmental contamination and accidental exposure.

Certain horse breeds have higher prevalence of EVA infection and therefore warrant particular attention regarding vaccination strategies. Standardbreds and Warmbloods have historically shown higher seroprevalence rates compared to other breeds, possibly related to breeding practices and population dynamics within these breeds. Stallions from high-prevalence breeds may be more likely to encounter EVA-positive mares or to have been previously exposed, making pre-vaccination testing and documentation particularly important for establishing their status.

Arabian horses and their crosses, while not showing unusually high EVA prevalence, may have breed-specific immune response characteristics worth considering. Arabians with Severe Combined Immunodeficiency should not receive any modified live virus vaccines, including EVA vaccine, as their inability to mount an immune response could result in vaccine-induced disease. Testing for SCID is available and recommended for Arabian foals from carrier lines before any live vaccine administration.

Draft breeds and warmbloods, due to their larger body size, do not typically require dose adjustments for EVA vaccine as the standard dose is designed to be effective across the range of horse sizes. However, injection site considerations may vary with muscle mass, and veterinarians may select different injection locations based on the individual horse's conformation. Draft breeds traveling to breeding facilities or competitions with horses from diverse backgrounds may face increased exposure risk and should have their EVA vaccination status addressed as part of comprehensive health planning.

Quarter Horses and related stock breeds have variable EVA seroprevalence depending on regional and management factors. The American Quarter Horse Association has specific requirements regarding EVA testing and vaccination for registered breeding stallions, and compliance with these requirements is essential for breeders. Horses with genetic conditions such as HYPP or PSSM should have their overall health status optimized before vaccination but do not have specific contraindications to EVA vaccine based on these conditions alone.

While EVA vaccine is the only product specifically designed to prevent equine viral arteritis, it exists within a broader context of equine immunization programs and disease prevention strategies. Understanding how EVA vaccination fits with other vaccines and preventive measures helps horse owners develop comprehensive health programs for their animals.

Core vaccines recommended for all horses by the American Association of Equine Practitioners include tetanus, Eastern and Western equine encephalomyelitis, West Nile virus, and rabies. These vaccines protect against diseases that pose significant risk to all horses regardless of geographic location or use. EVA vaccine, as a risk-based vaccine, is administered in addition to rather than instead of these core immunizations. Scheduling EVA vaccination within a comprehensive vaccine program requires coordination to avoid administering too many vaccines simultaneously.

Other risk-based vaccines that may be relevant to horses in EVA-risk situations include those for equine influenza and equine herpesvirus. Horses traveling to breeding facilities, shows, or competitions often face elevated risk for multiple respiratory and reproductive diseases, making a coordinated approach to risk-based vaccination appropriate. Influenza vaccination is particularly important for horses in contact with transient populations, and herpesvirus vaccination may be recommended for pregnant mares and horses at breeding facilities. The veterinarian will assess individual risk factors and recommend an appropriate combination of risk-based vaccines.

Biosecurity measures complement vaccination in preventing EVA transmission and should not be overlooked even in vaccinated populations. Quarantine protocols for new arrivals, testing of breeding horses, and careful management of semen for artificial insemination programs all contribute to EVA prevention. Vaccination provides individual protection but does not eliminate the need for facility-level biosecurity practices. An integrated approach combining appropriate vaccination with sound management practices provides the most robust protection against EVA and other infectious diseases of horses.